THE PATH TO **DIAGNOSING HEART HEALTH**

Approximately 50% of people who are at risk of heart disease are not identified by routine testing. The unique Heart Health testing by BioReference Laboratories supports better identification and treatment of the growing population of individuals with or at risk for atherosclerotic cardiovascular disease (ASCVD) through four clinically relevant panels.

The patient-friendly Heart Health report allows for improved treatment management, and promotes patient compliance with their care.

FEATURES INCLUDE:

Lipoprotein Particle Evaluation

Heart Health now includes a Lipoprotein Particle Evaluation that measures the lipoprotein subgroups, allowing healthcare providers to accurately determine and diagnose cardiovascular risk in patients.

Global Risk Calculations

Heart Health gives physicians the option of incorporating a Global Risk Calculation using Framingham, Reynold's or Pooled Cohort to assess patient risk for atherosclerotic cardiovascular disease (ASCVD) events.

Previous Results

Historical data listed on the Heart Health report allow physicians to quickly reference previous results and more easily monitor patient progress.

HEART HEALTH TESTING FROM BIOREFERENCE LABORATORIES IS A COMPREHENSIVE APPROACH TO DIAGNOSING AND MANAGING PATIENTS WHO HAVE OR MAY BE AT RISK FOR HEART DISEASE.

Markers	Relevance
HDL Cholesterol	High Density Lipoprotein (HDL) slows arterial plaque buildup by transporting the cholesterol to the liver for disposal.
HDL Particle Number	The HDL particle number corresponds to the amount of bad cholesterol disposed by the liver. Therefore, the higher the number, the more cholesterol is disposed.
HDL2b	Elevated levels of HDL2b and HDL3 are cardioprotective and are an indicator of how well excess lipids are removed from cells and transported back to the liver. Women tend to have higher levels than men. Reduced levels are associated with a risk of development of diabetes.
Hemoglobin A1c	Hemoglobin A1c (HbA1c) measures the average amount of sugar in your blood over a 3-month period and is used in the diagnosis and monitoring of diabetes. Diabetics are at an increased risk of ASCVD events.
hs-CRP	C-reactive protein (CRP) is an inflammatory protein; it is associated with inflammation of blood vessels and is associated with ASCVD, even in the absence of an elevated total cholesterol.
LDL Direct	Low Density Lipoprotein (LDL) can slowly build up in the inner walls of arteries, causing them to narrow.
LDL Particle Number	LDL particles transport cholesterol. The higher the number of LDL particles, the more carriers of cholesterol, and a greater risk for developing ASCVD.
LP(a) Excess	Lp(a) excess is the most commonly inherited lipid disorder in patients with premature coronary heart disease. Very high levels of Lp(a) are associated with elevated vascular risk.
Remnant Lipoprotein (RLP)	RLP is an atherogenic lipoprotein composed primarily of Very Low Density Lipoprotein (VLDL) and Intermediate Density Lipoprotein (IDL), and is believed to be a building block of plaque.
Small, dense LDL	Small, dense LDL are atherogenic particles that can easily penetrate the arterial endothelium and cause plaque formation.

HEART HEALTH PROFILES | COMPONENTS AND SPECIMEN REQUIREMENTS

HEART HEALTH PROFILES	COMPONENTS AND SPECIMEN REQUIREMENTS		
Comprehensive Heart Health Baseline Profile Test Code F306-6	CBC w/Diff; CMP Basic Lipid; LDL Direct; Lipoprotein Particle Evaluation; LP(a); hs-CRP; HbA1c	1 SST	1 Lavender
Heart Health Baseline Profile Test Code Q471-5	Basic Lipid; LDL Direct; Lipoprotein Particle Evaluation; LP(a); hs-CRP; HbA1c	1 SST	1 Lavender
Comprehensive Heart Health Monitoring Profile Test Code F307-4	CBC w/Diff; CMP Basic Lipid; LDL Direct Lipoprotein Particle Evaluation; hs-CRP; HbA1c	1 SST	1 Lavender
Heart Health Monitoring Profile Test Code Q472-3	Basic Lipid; LDL Direct; Lipoprotein Particle Evaluation; hs-CRP; HbA1c	1 SST	1 Lavender

*For Government Healthcare Programs, tests should be ordered individually and as needed, not in panel form.

Prevention and Early Detection

- Identifies at-risk patients otherwise missed with traditional lipid testing
- Enables clinicians to treat atherogenic lipoprotein profiles before overt dyslipidemia becomes apparent
- Includes markers that characterize dyslipidemia and prognosticate relevant outcomes.

Clinically Relevant Information

- Replaces traditional lipid testing for cardiometabolic risk and diabetic patients
- Provides global risk score to identify patient's 10-year projection ASCVD events, including Myocardial infarction (MI) and ASCVD death
- Includes tests endorsed by Heart Health organizations and guidelines including AHA, ACC, ADA, CDC and NCEP.
- Detects NCEP emerging risk factors, including Lp(a), RLP (Remnant Lipoprotein), HDL2b, and Small dense LDL
- Accurately measures the lipoprotein supgroups of VLDL, LDL, and HDL

Convenient Ordering* and Quick Reporting

- Complete test kit and transport provided
- Cost effective and covered by most insurances
- Results report available online
- Easy to understand interpretation of results for patients
- Fast turn-around-time gets your patients on the path to treatment

Additional Resources:

American Heart Association: www.aha.org

Cardiovascular Research Foundation: www.crf.org

Centers For Disease Control: www.cdc.gov/heartdisease

SAMPLE REPORT

REFERENCES:

1. Brunzell D., Davidson, et al. Lipoprotein Management in Patients with Cardiometabolic Risk. Diabetes Care 2008: 31 (4): 811-822.

2. Pearson TA, et al. Circulation. 2003;107:499-511. http://circ.ahajournals.org/cgi/content/full/107/3/499&

3. Ridker PM. Circulation. 2003;107:363-369. http://circ.ahajournals.org/cgi/content/full/107/3/363 from the website: http://usa.healthcare.siemens.com/clinicalspecialities/cardiology/cardiovascular-disease/educational-content/hscrp

4. http://jaha.ahajournals.org/content/2/2/e000077.full Pai JK, Cahill LE, Hu FB, Rexrode KM, Manson JE, Rimm EB. Hemoglobin A1cs Associated With Increased Risk of Incident Coronary Heart Disease Among Apparently Healthy, Nondiabetic Men and Women. J Am Heart Assoc. 2013; 2: e000077 originally published March 22, 2013, doi: 10.1161/ JAHA.112.000077

BioReference
LABORATORIES
an OPKO Health Company